<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406676</url>
  </required_header>
  <id_info>
    <org_study_id>MZK002</org_study_id>
    <nct_id>NCT03406676</nct_id>
  </id_info>
  <brief_title>Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance</brief_title>
  <official_title>The Preventive Effects of Pre-treatment With Methylene Blue for Vascular Paralysis of the Patients With Obstructive Jaundice During Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effects of pre-treatment with methylene blue on reduced perioperative vascular
      resistance in patients with obstructive jaundice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodynamic characteristics of patients with obstructive jaundice are high cardiac output,
      low peripheral vascular resistance. The molecular basis for this feature is the increased
      production of NO. Methylene blue can increase peripheral resistance, the mechanism is:
      methylene blue is an oxidoreductase inhibitor, can inhibit the increased production of NO in
      the vascular endothelium, thereby increasing peripheral vascular resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral vascular resistance</measure>
    <time_frame>through operation completion, an average of 6 hours</time_frame>
    <description>the dose of vasoconstrictors used to Maintain Peripheral vascular resistance in the normal range (800 ~ 1200dyns / cm5)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obstructive Jaundice</condition>
  <arm_group>
    <arm_group_label>Methylene blue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50ml of saline is administrated I.V before anesthesia induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.</description>
    <arm_group_label>Methylene blue</arm_group_label>
    <other_name>Methylene blue injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18-60 years;

          2. American Society of Anesthesiologists（ASA） grade I~III;

          3. TBIL＞ULN and TBA＞ULN; The patients with obstructive jaundice.

        Exclusion Criteria:

          1. Organs dysfunction(heart,lungs and etc);

          2. Mental disorders;

          3. in other clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng ShuGuo</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Study Director Institute of Hepatobiliary Surgery ,Southwest Hospital ,Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Jiaolin, Doctor</last_name>
    <phone>0086-15808014085</phone>
    <email>Njiaolin1976@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Jiaolin</last_name>
      <phone>0086-15808014085</phone>
      <email>Njiaolin1976@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Jiaolin, Doctor</last_name>
      <phone>0086-15808014085</phone>
      <email>Njiaolin1976@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Shuguo Zheng, MD</investigator_full_name>
    <investigator_title>Professor of Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University Affiliation: Southwest Hospital, China</investigator_title>
  </responsible_party>
  <keyword>Methylene blue; Peripheral vascular resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

